Anticoagulation dilemma in a high-risk patient with On-X valves

Ami M. Karkar, Manuel R Castresana, Nadine Odo, Shvetank Agarwal

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thromboembolism continues to be a major concern in patients with mechanical heart valves, especially in those with unsatisfactory anticoagulation levels. The new On-X valve (On-X Life Technologies, Austin, TX, USA) has been reported as having unique structural characteristics that offer lower thrombogenicity to the valve. We report a case where the patient received no or minimal systemic anticoagulation after placement of On-X mitral and aortic valves due to development of severe mucosal arterio-venous malformations yet did not show any evidence of thromboembolism. This case report reinforces the findings of recent studies that lower anticoagulation levels may be acceptable in patients with On-X valves and suggests this valve may be particularly useful in those in whom therapeutic levels of anticoagulation cannot be achieved due to increased risk of bleeding.

Original languageEnglish (US)
Pages (from-to)257-260
Number of pages4
JournalAnnals of Cardiac Anaesthesia
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Thromboembolism
Heart Valves
Aortic Valve
Mitral Valve
Hemorrhage
Technology
Therapeutics
austin

Keywords

  • Anticoagulation
  • On-X valve
  • Thromboembolism

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Anticoagulation dilemma in a high-risk patient with On-X valves. / Karkar, Ami M.; Castresana, Manuel R; Odo, Nadine; Agarwal, Shvetank.

In: Annals of Cardiac Anaesthesia, Vol. 18, No. 2, 01.02.2015, p. 257-260.

Research output: Contribution to journalArticle

@article{02b42ff9de1245a0b67bb44604e94672,
title = "Anticoagulation dilemma in a high-risk patient with On-X valves",
abstract = "Thromboembolism continues to be a major concern in patients with mechanical heart valves, especially in those with unsatisfactory anticoagulation levels. The new On-X valve (On-X Life Technologies, Austin, TX, USA) has been reported as having unique structural characteristics that offer lower thrombogenicity to the valve. We report a case where the patient received no or minimal systemic anticoagulation after placement of On-X mitral and aortic valves due to development of severe mucosal arterio-venous malformations yet did not show any evidence of thromboembolism. This case report reinforces the findings of recent studies that lower anticoagulation levels may be acceptable in patients with On-X valves and suggests this valve may be particularly useful in those in whom therapeutic levels of anticoagulation cannot be achieved due to increased risk of bleeding.",
keywords = "Anticoagulation, On-X valve, Thromboembolism",
author = "Karkar, {Ami M.} and Castresana, {Manuel R} and Nadine Odo and Shvetank Agarwal",
year = "2015",
month = "2",
day = "1",
doi = "10.4103/0971-9784.154496",
language = "English (US)",
volume = "18",
pages = "257--260",
journal = "Annals of Cardiac Anaesthesia",
issn = "0971-9784",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Anticoagulation dilemma in a high-risk patient with On-X valves

AU - Karkar, Ami M.

AU - Castresana, Manuel R

AU - Odo, Nadine

AU - Agarwal, Shvetank

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Thromboembolism continues to be a major concern in patients with mechanical heart valves, especially in those with unsatisfactory anticoagulation levels. The new On-X valve (On-X Life Technologies, Austin, TX, USA) has been reported as having unique structural characteristics that offer lower thrombogenicity to the valve. We report a case where the patient received no or minimal systemic anticoagulation after placement of On-X mitral and aortic valves due to development of severe mucosal arterio-venous malformations yet did not show any evidence of thromboembolism. This case report reinforces the findings of recent studies that lower anticoagulation levels may be acceptable in patients with On-X valves and suggests this valve may be particularly useful in those in whom therapeutic levels of anticoagulation cannot be achieved due to increased risk of bleeding.

AB - Thromboembolism continues to be a major concern in patients with mechanical heart valves, especially in those with unsatisfactory anticoagulation levels. The new On-X valve (On-X Life Technologies, Austin, TX, USA) has been reported as having unique structural characteristics that offer lower thrombogenicity to the valve. We report a case where the patient received no or minimal systemic anticoagulation after placement of On-X mitral and aortic valves due to development of severe mucosal arterio-venous malformations yet did not show any evidence of thromboembolism. This case report reinforces the findings of recent studies that lower anticoagulation levels may be acceptable in patients with On-X valves and suggests this valve may be particularly useful in those in whom therapeutic levels of anticoagulation cannot be achieved due to increased risk of bleeding.

KW - Anticoagulation

KW - On-X valve

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84927671925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927671925&partnerID=8YFLogxK

U2 - 10.4103/0971-9784.154496

DO - 10.4103/0971-9784.154496

M3 - Article

C2 - 25849704

AN - SCOPUS:84927671925

VL - 18

SP - 257

EP - 260

JO - Annals of Cardiac Anaesthesia

JF - Annals of Cardiac Anaesthesia

SN - 0971-9784

IS - 2

ER -